Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8840757 | 0.86 | FGFR1 (0.35) | ADORA2AADORA1FGFR1LMNATHRB | |
| SCHEMBL8371869 | 0.85 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL22402203 | 0.85 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL3260489 | 0.85 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL20156720 | 0.85 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL9151037 | 0.85 | FGFR1 (0.40) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL24082118 | 0.82 | FGFR1 (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL20806276 | 0.82 | FGFR1 (0.33) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL22779434 | 0.82 | JAK2 (0.36) | ADORA2AADORA1FGFR1LMNATHRB | |
| SCHEMBL12096477 | 0.82 | FGFR1 (0.39) | FGFR1LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4081653-B1 | METHODS FOR LONG READ SEQUENCING | SINGULAR GENOMICS SYSTEMS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240209408-A1 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | CODEXIS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209408-A1 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | CODEXIS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024129235-A1 | ENZYMATIC SYNTHESIS OF NTP AND NQP | CODEXIS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023215761-A1 | LOCALIZATION OF TRANS-SPLICING NUCLEIC ACID MOLECULES TO AND WITHIN THE CELLULAR NUCLEUS | TACIT THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023212369-A1 | NUCLEOTIDE CYCLIC CLEAVABLE MOIETIES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7339054-B2 | Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates | MERCK & CO., INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7339054-B2 | Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates | MERCK & CO., INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | ADORA2A 1751/4885ADORA1 1203/4885FGFR1 842/4885 |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | ADAR, FUT5, CSGALNACT1 | ADORA2A 34/4885ADORA1 77/4885FGFR1 2600/4885 |
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | ADORA2A 131/4885ADORA1 22/4885FGFR1 1605/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ADORA2A 3655/4885ADORA1 1163/4885FGFR1 1431/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA2A 368/4885ADORA1 344/4885FGFR1 2033/4885 |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | ADORA2A 3755/4885ADORA1 4188/4885FGFR1 3799/4885 |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | DUT, RNGTT, DPYD | ADORA2A 81/4885ADORA1 220/4885FGFR1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.